|
|||||
|
|
Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced,unresectable hepatocellular carcinoma |
|
| Authors: | Lynn G. Feun MD Ying-Ying Li PhD Chunjing Wu MS Medhi Wangpaichitr PhD Patricia D. Jones MD Stephen P. Richman MD Beatrice Madrazo MD Deukwoo Kwon PhD Monica Garcia-Buitrago MD Paul Martin MD Peter J. Hosein MD Niramol Savaraj MD |
| Affiliation: | 1. Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida;2. Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida;3. Division of Hematology and Oncology, Miami Veterans Affairs Healthcare System, Miami, Florida;4. Department of Surgery, University of Miami Miller School of Medicine, Miami, Florida;5. Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida;6. Department of Radiology, University of Miami Miller School of Medicine, Miami, Florida;7. Biostatistics and Bioinformatics Shared Resource, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida;8. Department of Pathology, University of Miami Miller School of Medicine, Miami, Florida;9. Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida Division of Hematology and Oncology, Miami Veterans Affairs Healthcare System, Miami, Florida |
| Abstract: | |
| Keywords: | circulating biomarkers clinical trial hepatocellular carcinoma pembrolizumab programmed death–ligand 1 (PD-L1) expression sorafenib |